Navigation Links
FDA Awards Precision Antibody Contract to Develop Monoclonal Antibodies for Influenza Vaccine Potency Assays
Date:10/19/2011

COLUMBIA, Md., Oct. 19, 2011 /PRNewswire-iReach/ -- Precision Antibody™ announced today its selection by the United States Food and Drug Administration (FDA) to develop monoclonal antibodies to influenza virus antigens for both Influenza A and B.  These antibodies will be used for in vitro assays to develop new vaccine potency assays. The term of the monoclonal development and antibody production contract is for one year with the option of five additional years.

On average, 5% to 20% of the U.S. population annually gets the flu.  Over 200,000 people are hospitalized from flu complications with around 24,000 people succumbing to flu-related causes. There are two main types of influenza -- type A and type B -- both of which are responsible for the yearly flu outbreaks.  Influenza B is specific to humans and can appear at any time of the year.  Influenza A, which can be found in many kinds of animals including ducks, chickens and pigs, is comprised of 16 different subtypes.  It normally arrives in early winter and spring, with the most well-known outbreak being the 2009 H1N1 influenza.

Current vaccine potency assays require an influenza strain-specific antigen standard and a strain-specific antibody standard.  These standards are made for each new strain, included in the annual vaccine.  This process must be repeated each year.  The FDA is interested in stream lining the process by developing monoclonal antibodies that are type-specific rather than strain-specific, so they can be more broadly used to assay the potency of all vaccine strains of a particular influenza subtype.  Precision Antibody will apply its proprietary rapid antibody development technology to generate type-specific antibodies for up to 20 different influenza targets for the FDA.

"Since timely preparation of potency reagents by regulatory authorities is challenging and always a potential bottleneck in influenza vaccine production," said Dr. Falko Schmeisser. "It is extremely important that additional approaches for reagent development be available, particularly in the event of an emerging pandemic influenza virus like the H1N1 in 2009."  Dr. Jun Hayashi, V.P. of Precision Antibody, said "we are honored to be selected and excited to be working with the FDA to develop these important antibodies. We are looking forward to initiating and growing this working relationship with Dr. Schmeisser's group."

About the Contract

This project HHSF223201110981P is supported with federal funds provided by the United States Food and Drug Administration (FDA). The content of this press release does not necessarily reflect the views or policies of the FDA, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

About Precision Antibody (www.precisionantibody.com)

Precision Antibody provides customized, high-affinity monoclonal antibodies to pharmaceutical and biotechnology companies as well as to academic, government, and nonprofit research institutions for use in discovery, research, and testing of novel pharmaceuticals, biomarkers, and diagnostic tests. Precision Antibody is a one-stop service for antibody development, characterization (affinity determination by Biacore analysis), purification/production (from pilot to large scale), and conjugation, as well as stable cell line development, humanization, and hybridoma cell banking. Precision Antibody is a wholly owned service division of A&G Pharmaceutical, Inc. (www.agpharma.com) and is based in Columbia, MD.

Media Contact: Michael Keefe Precision, Antibody, 410-884-4100, mkeefe@precisionantibody.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Precision Antibody
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
2. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
3. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
4. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
5. Small Business Innovation Research Program Awards Grant to Biomoda
6. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
7. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
8. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
9. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
10. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
11. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016   National Community Pharmacists Association ... issued the following statement today in response to the ... the Centers for Medicare & Medicaid Services (CMS) and ... advocates and others: patient advocacy organizations ... reviewing the full CMS analysis. Our initial reaction is ...
(Date:2/12/2016)... 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery in ... Okaloosa County Emergency Medical Services (EMS) consisting ... one LT2 van. Quality Emergency Vehicles in Lecanto, ... the sale.  This is the latest in Demers, ongoing expansion ... President at Demers. --> Benoit LaFortune , Executive ...
(Date:2/12/2016)... , Feb. 12, 2016  Memorial Hermann Health ... Dwight Howard to bring a one-of-a-kind experience ... . Using cutting-edge technologies such as 360-degree video and ... both virtually, then literally – giving the patients and ... and it was all caught on video . ...
Breaking Medicine Technology:
(Date:2/12/2016)... Washington, DC (PRWEB) , ... ... ... the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to ... settings. The partnership will recruit top students from U.S. universities who will ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose ... – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose ... products, garnering increased attention from all stakeholders in the development of new chemical ...
(Date:2/12/2016)... ... 12, 2016 , ... Coco Libre, the maker of coconut water beverages with ... Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic ... The invitation-only gifting suite, held this year at the W Hollywood Hotel, has become ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... as a Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) ... channel partners to offer real-time business intelligence (BI) to their small and medium ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a ... initiating a charity drive that will raise funds earmarked to purchase computers and software ... Elementary School. , “My school is in a low-income area and has more than ...
Breaking Medicine News(10 mins):